This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Two pharmaceutical stocks demonstrate portfolio pitfalls and rewards

Stocks in this article: ARNA THRX

By Chris Lau for Kapitall.

Obesity is a medical problem that now has drug treatment options. Prior to FDA approval, investor interest in Arena Pharmaceuticals (ARNA) soared. Since the FDA approved Belviq, Arena began to market and sell the drug. Sales are steady but not as strong as initially thought. This creates an opportunity in pharmaceutical stocks for investors with a long term time horizon.

Arena results miss

Arena reported quarterly results on May 12 2014 that missed consensus estimates. The company lost $0.12 per share on revenue of $6.8 million. The weak results validated the short-selling thesis for the bears. Moreover, the short float is high, at 23.19 percent.

Despite the short-term challenges, Arena is showing improving business performance. Expenses rose 29.9 percent in Q1, compared to the 183.3% growth in revenue. Prescriptions are also up 31% (based on IMS Health data). Institutional ownership is strong. Most importantly, Arena and its partner Eisai are expanding its sales force and availability worldwide.

In the value space, Theravance (THRX) is down nearly 35 percent from its yearly high. Short float is 22.3%. Theravance reported weak quarterly earnings on May 6. The company reported revenue of just $0.17 million and a loss of $0.62 per share. To boost shareholder value and to become more focused, Theravance is spinning out Theravance Biopharma on June 2. Biopharma will hold the “discovery, development, and commercialization of small molecule product candidates” in such areas as bacterial infections and respiratory diseases. Theravance Inc. will become a Royalty Management Company. The latter will begin paying a dividend of $0.25 per share quarterly.

Risks still high

Stock price volatility will be the biggest risk for Theravance and Arena in the near term, but the future for both companies is bright. Investors should add these two companies to their watch list and consider buying them on weakness.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs